HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.

AIMS: It has been reported that 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors increase bone mineral density (BMD) in vivo. We investigated the effect of HMG-CoA reductase inhibitors on BMD in patients with Type 2 diabetes mellitus. PATIENTS AND METHODS: We selected 122 patients with Type 2 diabetes, who were not taking active vitamin D preparations. Their mean age was 67.3 +/- 9.2 years. They were divided into a control group (n=63) without HMG-CoA reductase inhibitor therapy and an HMG-CoA group (n=59) who were treated with these drugs. The BMD of the distal one-third of the radius was measured by dual-energy X-ray adsorptiometry at baseline and after 2 years. RESULTS: There were no significant differences between the control and HMG-CoA groups at baseline with respect to age, gender, body mass index, duration of diabetes, haemoglobin A1c, fasting plasma glucose, adjusted calcium, serum phosphorus, alkaline phosphatase, albumin excretion rate and radial BMD. However, there was a significantly smaller annual decrease of the radial BMD in the HMG-CoA group. Multiple regression analysis with a forward elimination procedure revealed a positive correlation of the radial BMD Z-score with body mass index, while there was a negative correlation with alkaline phosphatase and albumin excretion rate. In addition, the annual rate of change of the radial BMD showed a positive correlation with HMG-CoA reductase inhibitor therapy. CONCLUSIONS: These findings suggest that HMG-CoA reductase inhibitors may prevent bone loss in patients with Type 2 diabetes.     

噻唑烷二酮类降糖药物与骨质疏松症

噻唑烷二酮类降糖药物因能改善胰岛素抵抗,临床广泛用于2型糖尿病、多囊卵巢综合征及非酒精性脂肪肝的治疗。最近研究结果提示,噻唑烷二酮类降糖药物在改善胰岛素抵抗降血糖的同时,可提高骨质疏松症及骨质疏松骨折的风险。本文综述了噻唑烷二酮类降糖药物致骨丢失的相关证据和增加骨质疏松症及骨质疏松骨折风险的可能病理机制,并探讨其临床防治策略。     

Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia

Summary.  Osteoporosis in adult males is an under-recognized problem. Patients with haemophilia have several predisposing factors for developing decreased bone mineral density (BMD) including prolonged periods of immobility, reduced weight bearing and co-morbidities associated with bone loss. To establish prevalence and risk factors associated with decreased BMD in patients with haemophilia. Adults with moderate or severe haemophilia A or B underwent dual-energy X-ray absorptiometry (DXA). BMD was correlated to laboratory values, joint mobility measurements and physical activity questionnaires. Thirty patients completed evaluations. The median age was 41.5 years (range 18–61). Median lowest T-score by DXA was −1.7 (range: −5.8 to +0.6), with the femoral neck being the site of the lowest T-scores. Based on World Health Organization criteria, 70% of patients had decreased BMD. Twenty-seven per cent of the participants ( n  = 8) had osteoporosis and 43% ( n  = 13) had osteopenia. Variables associated with increased bone loss included lower serum 25-hydroxyvitamin D levels ( P  = 0.03), lower body mass index ( P  = 0.047), lower activity scores ( P  = 0.02), decreased joint range of motion ( P  = 0.046), HIV ( P  = 0.03), HCV ( P  = 0.02), history of inhibitor ( P  = 0.01) and age ( P  = 0.03). Adults with haemophilia are at increased risk for developing osteoporosis. A history of HCV and HIV infections, decreased joint range-of-motion, decreased activity levels, history of an inhibitor and low body weight predict bone loss and suggest a population to target for screening. A high prevalence of vitamin D insufficiency was observed. Future studies should investigate interventions, including vitamin D supplementation, to prevent bone loss and fractures for this at-risk population.     

老年2型糖尿病发生骨质疏松的临床多因素分析

目的 探讨老年2型糖尿病(T2DM)患者发生骨质疏松的影响因素. 方法 根据患者的骨密度值将患者分为骨量正常(NOP)组、低骨量(LBMD)组、骨质疏松(OP)组,对比3组在年龄、糖尿病病程、体质量指数(BMI)、胱抑素C(Cys C)、经皮氧分压检查(TcPO2)、糖化血红蛋白(HbA1c)、尿C肽(U-CP)等指标之间的差异,并进行相关性分析. 结果 (1)与NOP组相比,LBMD及OP组年龄、病程显著性升高,U-CP显著性下降;(2)OP组BMI、Cys C显著低于NOP组;(3)OP组年龄显著高于LBMD组,而BMI显著低于LBMD组(P＜0.05或P＜0.01).老年T2DM患者的BMD与年龄、病程呈负相关,与BMI、U-CP呈正相关.逐步多元回归分析显示U-CP是BMD的正性预测因子. 结论 老年T2DM患者并发骨质疏松与多因素有关,包括高龄、低体质量、病程长、胰岛功能差等.     

Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes

Aims To determine the prevalence and biochemical/hormonal determinants of osteopenia and osteoporosis in adults with Type 1 diabetes. Methods One hundred and two patients (52 female, 50 male) with Type 1 diabetes aged 20–71 years underwent cross‐sectional assessment of biochemical/hormonal markers of bone metabolism, and bone mineral density (BMD) measurement at forearm, hip and spine using dual energy x‐ray absorptiometry. BMD data were available for 102 age‐ and gender‐matched population‐based control subjects. Results After adjusting for age and body mass index (BMI), osteopenia and osteoporosis were more common at the spine in males with Type 1 diabetes than in control subjects (P = 0.030). In Type 1 males, after adjustment for age and BMI, BMD, T‐ and Z‐scores at the hip, femoral neck and spine were lower compared with age‐matched control subjects (P ≤ 0.048). Female Type 1 patients and control subjects had similar BMDs and T‐ and Z‐scores at all sites. On multiple linear regression analysis, which adjusted for the natural logarithm of the sex hormone binding globulin concentration, smoking status and alcohol consumption, and (for women) menopausal status, each of BMI, serum ionized calcium and serum alkaline phosphatase (negatively) were independently associated with BMD at the hip and femoral neck in Type 1 diabetic subjects. Conclusions Adult males with Type 1 diabetes have reduced bone density at the hip, femoral neck and spine when compared with age‐matched control subjects. Impaired bone formation may occur in Type 1 diabetes.     

血清IL-6水平与2型糖尿病患者骨质疏松关系的探讨

目的 探讨血清白介素-6（IL-6）水平与2型糖尿病（T2DM）患者骨质疏松的关系。方法 测定74例T2DM患者及46例年龄、体重指数（BMI）相匹配的健康对照者的血清IL-6水平、骨密度（BMD）、血清骨钙素（BGP）、抗酒石酸磷酸酶（TRAP）、尿羟脯氨酸CHOP）,两组进行比较。结果 血清BGP、BMD水平T2DM患者明显低于对照组（P〈0.01,P〈0.05）;TRAP、尿HOP、血清IL-6水平显著高于对照组（P〈0.05）,IL-6与BMD呈显著负相关。结论 T2DM患者骨密度降低,其原因与IL-6水平升高有一定关系。     

2型糖尿病与男性骨质疏松

2型糖尿病 （type 2 diabetes mellitus,T2DM）和骨质疏松（osteoporosis,OP）是常见老年病.女性糖尿病患者的骨质疏松问题已受到广泛关注,而男性T2DM患者随年龄增长,同样存在骨代谢异常或骨质疏松等合并症,若不及时治疗,后果与女性一样严重.本文就近年对于男性T2DM患者骨密度研究进展、胰岛素、雄激素、骨转换标志物变化以及降糖药物对骨代谢的影响作一综述.     

Setting up an osteoporosis fracture liaison service: background and potential outcomes

A large evidence base now exists for treatment interventions that will reduce fracture risk. However, the key area of practice now is how to get this evidence base into clinical practice. All health-care systems are subject to financial constraints, and therefore it is important that all areas of clinical practice can demonstrate that they are able to deliver care in a cost-effective manner. It has become increasingly recognized within the area of osteoporosis that treatment interventions should be targeted at patients at the highest absolute risk of fracture in order to maximize the cost-effectiveness of the service. One key subgroup of patients who are at higher absolute fracture risk are patients who present with an incident fracture. Although it has long been recognized that this is a key group to be considered for investigation and intervention, it is also clear that any form of structured care for this group has not been developed. This chapter will review the background and practical aspects of running a fracture liaison service. This service addresses the issue of secondary prevention of fracture while also considering both the absolute risk of fracture and the absolute benefit of the intervention. Issues relating to the background evidence base underpinning the service as well as the practical issues relating to the actual running of a service are discussed. Some of the potential service outcomes are also reviewed.     

中青年甲状腺功能亢进患者骨密度特点

目的分析中青年甲状腺功能亢进(甲亢)患者骨密度特点及其与病程、病情严重程度的关系。方法使用双能X线骨密度仪分别测定340例中青年甲亢患者及160名年龄匹配的正常对照者的前臂、腰椎及股骨颈骨密度,用化学发光法测定甲亢患者游离三碘甲腺原氨酸(FT3)、游离甲状腺激素(FT4)及促甲状腺激素(TSH),用自动生化仪检测血清钙(Ca)、血清磷(P)、碱性磷酸酶(ALP),比较2组间骨密度及Ca、P、ALP的差异。根据国际临床骨密度学会(ISCD)和国际骨质疏松基金会(IOF)对中青年骨质疏松诊断的不同定义分别将甲亢患者分为骨量正常组(ON1)和骨质疏松组(OP1)、骨量正常组(ON2)、骨量减少组(OD2)、骨质疏松组(OP2),比较使用2种诊断方法得出的骨质疏松检出率,比较各组甲状腺激素(TH)及TSH的差异。结果与正常对照组相比,甲亢患者桡骨全部、腰椎L2-4及股骨颈骨密度均明显降低(均P0.05)。根据ISCD定义得出的骨质疏松检出率为46.8%,根据IOF定义得出的骨质疏松检出率为27.1%,前臂较腰椎、股骨颈骨密度降低更明显。甲亢患者骨质疏松组较骨量正常组的FT3、FT4明显升高(P0.05),TSH明显降低(P0.05)。多元线性回归分析显示桡骨骨密度与FT4、Ca呈负相关,与TSH呈正相关。结论中青年甲亢患者骨质疏松患病率高,骨量丢失较明显的部位为桡骨,过量甲状腺激素及低TSH均可导致骨代谢紊乱。     

强直性脊柱炎患者骨密度随年龄的变化

目的 采用双能X线吸收法测量强直性脊柱炎患者(AS)不同部位的骨密度(BMD),探讨其与年龄变化的关系,为临床防治AS患者BMD降低提供参考.方法 选取门诊50例符合纽约诊断标准的AS患者,按年龄≤40岁、年龄＞ 40岁分为两组,分别检测其侧位腰椎(L1-L4)、股骨颈、髋关节BMD,以T值≤-1.0定义为BMD降低,包括骨量减少(-2.5＜T＜-1.0)与骨质疏松(T≤-2.5).结果 两组AS患者出现BMD降低的比例均高于正常人,且年龄＞ 40岁组其腰椎BMD减少的比例高于年龄≤40岁组(P＜0.05),而其腰椎平均T值低于年龄≤40岁组(P＜0.05),在股骨颈测得的BMD、骨质疏松比例两组无明显差异(P＞0.05).结论 AS患者早期即可出现骨量减少甚至骨质疏松,随着年龄的增长其侧位腰椎BMD降低明显,骨折风险增大.临床上应当提高对AS合并骨质疏松的警惕,及时予补钙等治疗,提高患者的生活质量.     

A risk assessment tool (OsteoRisk) for identifying latin American women with osteoporosis

OBJECTIVE: To develop a simple and easy-to-use tool for identifying osteoporotic women (femoral neck bone mineral density [BMD] T-scoresor=50 in Latin America who had femoral neck BMD measurements. MEASUREMENTS AND MAIN RESULTS: A risk index was developed from 1,547 patients based on least square regression using age, weight, history of fractures, and other variables as predictors for BMD T-score. The final model was simplified by reducing the number of predictors; sensitivity and specificity were evaluated before and after reducing the number of predictors to assess performance of the index. The final model included age, weight, country, estrogen use, and history of fractures as significant predictors for T-score. The resulting scoring index achieved 91% sensitivity and 47% specificity. Simplifying the index by using only age and weight yielded similar performance (sensitivity, 92%; specificity, 45%). Three risk categories were identified based on OsteoRisk, the index using only age and body weight: high-risk patients (index <=-2; 65.6% were osteoporotic), moderate-risk patients (-2< index <=1; 26.7% were osteoporotic), and low-risk patients (index>1; 8% were osteoporotic). Similar results were seen in a validation sample of 279 women in Brazil. CONCLUSION: Age and weight alone performed well for predicting the risk of osteoporosis among postmenopausal women. The OsteoRisk is an easy-to-use tool that effectively targets the vast majority of osteoporotic patients in Latin America for evaluation with BMD.     

Diabetes and skeletal health

Osteoporosis and diabetes affect a large proportion of the elderly population. The prevalence of diabetes and osteoporosis is increasing. Compared with individuals without diabetes, both men and women with diabetes have a higher risk of fractures, particularly at the hip, with consequent significant morbidity and mortality. Type 1 diabetes is associated with decreased bone mass and although bone mass data for Type 2 diabetes may or may not be decreased, there is evidence of altered bone quality in diabetes. The mechanisms involved include effects of insulin, insulin-like growth factor 1, cytokines, advanced glycation end products, and altered calcium homeostasis. In addition, a drug-induced increase in the incidence of fractures has been noted with the use of thiazolidinediones (TZDs). TZDs improve insulin sensitivity and have multitude other beneficial effects. Osteoblasts and adipocytes are derived from a common multipotential mesenchymal stem cell progenitor, with activation of peroxisome proliferator-activated receptor γ2 by both currently available TZDs (i.e. rosiglitazone and pioglitazone) stimulating adipogenesis and inhibiting osteoblastogenesis. The use of both rosiglitazone and pioglitazone is associated with an increased fracture risk, with changes in bone turnover markers and decreased bone mineral density.     

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis

Osteoporosis in men is an increasingly recognized problem with associated fracture morbidity and mortality. Treatment is limited, with the bisphosphonates being the mainstay of therapy. Risedronate has demonstrated fracture efficacy in women and efficacy has been recently been investigated in men. In men, risedronate either maintains or increases bone mineral density. In placebo controlled trials it has been shown to be safe and effective in preventing fractures.     

Association between serum uric acid and bone mineral density in patients with type 2 diabetes: A 6-year longitudinal study in China

The relationship between serum uric acid (UA) and bone mineral density (BMD) has been proposed by several researchers. However, there has been no consensus regarding the relationships among serum UA, diabetes, and BMD. The aim of this study is to investigate the association between UA, BMD, and at least osteopenia in type 2 diabetes patients.This research was a longitudinal study performed at Xiao-Tang-Shan Hospital in Beijing. Type 2 diabetes diagnosis was consistent with the WHO standard classification. Participants with osteopenia or osteoporosis documented by dual-energy X-ray absorptiometry were defined as having “at least osteopenia.” A generalized additive model and multivariable logistic regressions were performed to explore the relationship between serum UA and at least osteopenia. Receiver operating characteristic analysis was conducted. Propensity score matching was used to verify the correctness of the cutoff point.In total, 3476 type 2 diabetes patients free of any osteopenia-related diseases were recruited in 2012 and followed up to 2018. The general proportions of patients with at least osteopenia in 2018 was 16.46% (572/3476). Serum UA was negatively associated with BMD stratified by sex, age group, and BMI level. Setting the first quartile as the reference, the risk of at least osteopenia in the fourth quartile was significant among all patients (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.57, 0.98) and specifically in females (OR: 0.79; 95% CI: 0.43, 0.97), patients aged over 50 years (OR: 0.79; 95% CI: 0.60, 0.97) and patients with a BMI greater than 25 (OR: 0.74; 95% CI: 0.47, 0.97). The optimal cutoff point for the serum UA level to distinguish at least osteopenia in diabetic patients was 395 μmol/L.Serum UA concentration is negatively associated with the occurrence of at least osteopenia in Chinese patients with type 2 diabetes.     

Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis

OBJECTIVES: Osteoporosis is a well-known extra-articular phenomenon in patients with uncontrolled, long-standing rheumatoid arthritis (RA). In the present study, the extent of osteoporosis and reduced bone mineral density (BMD) and the disease-related and demographic factors that are associated with osteoporosis and reduced BMD were examined in patients with recently diagnosed, active RA. METHODS: BMD of the total hip and the lumbar spine was measured using dual-energy x ray absorptiometry in 381 patients with recently diagnosed active RA, who had never been treated with DMARDs or corticosteroids. Osteoporosis was defined as a T score 相似文献   

Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes.

AIMS: To measure bone density and neuropathy in both feet in Type 1 and Type 2 patients with unilateral Charcot osteoarthropathy and controls. METHODS: Calcaneal bone density, temperature and vibration thresholds were compared between 17 Type 1 diabetic patients with osteoarthropathy and 47 Type 1 controls and between 18 Type 2 diabetic patients and 48 Type 2 controls. As well as the Charcot foot, the non-Charcot foot was studied to assess osteopenia at onset of osteoarthropathy. RESULTS: In Type 1 diabetes, bone density was reduced in the non-Charcot foot compared with controls [Z-score: -1.7 ({-1.9}-{-1.4}) vs. -0.2 ({-1.1}-{0.5}), P < 0.0001, median (interquartile range)]; but not in Type 2 diabetes [Z-score: 0.15 ({-0.45}-{0.85}) vs. 0.3 ({-0.5}-{0.9}), P = 0.675]. Bone density in the Charcot foot was lower compared with the non-Charcot foot in both Type 1 [Z-score: -2.0 ({-2.8}-{-1.4}) vs. -1.7 ({-1.9}-{-1.4}), P = 0.018] and Type 2 diabetes [Z-score: -0.2 ({-1.4}-{0.1}) vs. 0.3 ({-0.5}-{0.9}), P = 0.001]. In Type 1 diabetes, bone density of the non-Charcot foot was reduced compared with that in Type 2 (P < 0.0001). Body mass index was lower in Type 1 than in Type 2 Charcot patients (P = 0.007). Type 2 patients had high temperature (P = 0.001) and vibration thresholds (P < 0.0001) in the non-Charcot foot compared with Type 2 controls whereas Type 1 patients had a high temperature threshold (P = 0.01) but not vibration threshold compared with Type 1 controls (P = 0.077). CONCLUSION: Bone density was reduced in the non-Charcot foot in Type 1 but not in Type 2 diabetes. Type 2 patients had high temperature and vibration thresholds in contrast to Type 1 patients who had a high temperature threshold only.     

Longitudinal study of bone mineral density in patients with Crohn's disease

Osteoporosis is frequent in Crohn's disease. The aim of the study was to assess the rate of bone loss over time retrospectively and the influence of disease-related factors on bone loss. Twenty-nine patients (8 male), admitted for repeated bone mineral density assessments (BMD) were enrolled. BMD measured by dual energy x-ray absoptiometry was expressed in grams per square centimeter, and as sex- and age-matched Z score. The mean interval between BMD assessments was 41 months, during which period 27 patients used corticosteroids (mean dose 8.6 g) and 21 patients some form of bone protective medication. Initial Z scores at a mean age of 41 years were significantly below zero (spine –1.6 ± 1.4; femur –1.4 ± 1.4). Over time, no change in absolute BMD was observed accompanied by an improvement in Z scores. At the same time, an increase in body weight and a decrease in erythrocyte sedimentation rate (ESR) was observed. Multilinear regression analysis demonstrated change in ESR as independent predictor for change in femoral Z score. In conclusion, low BMD is frequent in Crohn's disease, but decline of BMD over time was not found, despite ongoing use of corticosteroids.     

老年髋部骨折患者肌肉减少症与骨密度的关系

目的探讨老年髋部骨折患者肌肉减少症(sarcopenia)及与骨密度下降的关系。方法 113例65岁的老年髋部骨折患者(骨折组)纳入本研究,男性67例,女性46例;同期非髋部骨折老年患者1 321例作为对照组,男性654例,女性667例。所有患者均用双能X线骨密度仪(DXA)检测全身身体组成成分(骨量、肌肉含量,脂肪含量)。肌肉减少症的诊断标准:骨骼肌重量指数(SMI)(肢体骨骼肌重量/身高平方,kg/m2)低于同人种健康成年人1个标准差为1级肌肉减少症(class 1),低于2个标准差为2级肌肉减少症(class 2)。根据以上标准将受试者分为肌量正常组:男性SMI7.01 kg/m2,女性SMI5.42 kg/m2;class 1组:男性SMI 6.09~7.01 kg/m2,女性SMI 4.80~5.42 kg/m2;class2组:男性SMI≤6.08 kg/m2,女性SMI≤4.79 kg/m2。分析不同组老年髋部骨折患者肌肉减少症的检出率。结果老年髋部骨折患者肌肉减少症检出率明显高于同性别类似年龄人群:骨折组男性肌肉减少症检出率(62.6%)与对照组男性肌肉减少症检出率(12.8%)比较差异有统计学意义(P0.001),骨折组女性肌肉减少症检出率(13.0%)与非骨折组女性肌肉减少症检出率(4.1%)比较差异有统计学意义(P0.001);老年女性髋部骨折患者中肌量正常者24例(52.1%),Class 1级者16例(34.7%),Class 2级者6例(13.0%);骨骼肌重量指数与股骨颈骨密度和全身骨密度呈正相关。老年男性髋部骨折患者中肌量正常者9例(13.4%),Class 1级者16例(23.8%),Class 2级者42例(62.6%),骨骼肌重量指数与BMI呈正相关,与年龄呈负相关。结论老年髋部骨折患者肌肉减少症检出率明显高于同龄非骨折者,男性肌少症检出率高于女性。老年女性髋部骨折患者的骨骼肌重量指数与股骨颈和全身骨密度呈正相关,老年男性髋部骨折患者骨骼肌重量指数则与骨密度无明显相关性。应关注骨折患者肌肉减少症的防治。